CT-132 Outcome of Sex-Mismatched Allogeneic Hemopoietic Stem Cell Transplantation from Human Leukocyte Antigen–Identical Sibling Donors in Patients With Hematologic Diseases

Abstract

Hematopoietic stem cell transplantation is a procedure aiming to cure hematologic diseases. However, graft-versus-host disease (GVHD) and disease relapse/failure are common side effects of this treatment. Sex-mismatched transplantation, particularly with female donors and male patients, is known to be associated with higher incidence of GVHD or lower incidence of survival. This is caused by the antibodies against minor histocompatibility antigens found on the Y chromosome of the male recipient, which were found to be associated with increased risk of chronic GVHD and non-relapse mortality. The study aimed to determine the incidence of acute and chronic GVHD, overall survival, and non-relapse mortality when male patients received stem cells from female matched sibling donors in allogeneic hematopoietic stem cell transplantation. Retrospective study over 8 years. Nasser Institute Hospital. In this study, patients were divided into 2 groups. Group 1: female donors to male patients (245 patients). Group 2: male donors to female patients (186 patients) and same-sex donors and patients (506 patients). The median age was 20 years (7 months-60 years). The outcome of transplants in the female-to-male group was compared with that of the male-to-female and same-sex group. Overall survival, incidence of acute and chronic GVHD, non-relapse mortality, and relapse/failure rate. Overall survival was 68.6% in group 1 compared to 69.5% in group 2 (P=0.5). Acute GVHD was 24% in group 1 compared to 19.6% in group 2 (P=0.1). Chronic GVHD was 15.1% in group 1 compared to 9.6% in group 2 (P=0.02). Non-relapse mortality was 27.7% in group 1 compared to 25.7% in group 2 (P=0.5). Relapse/failure rate was 4.9% in group 1 compared to 6.5% in group 2 (P=0.3). Allogeneic stem cell transplantation for male patients from female donors can be associated with a significantly higher rate of chronic GVHD but a lower incidence of relapse/failure.